UBE2L6

Across TCGA pan-cancer cohorts, UBE2L6 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of UBE2L6’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where UBE2L6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types UBE2L6 is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

HNSC, KIRC, and COAD are the cancer types where UBE2L6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in UBE2L6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	+1.486	<.001	12	view →
KIRC	Male	IV	+1.369	<.001	12	view →
COAD	All	II,III,IV	+0.849	<.001	9	view →
STAD	All	II,III,IV	+0.943	.002	8	view →
BRCA	All	III,IV	+1.152	<.001	6	view →
BLCA	All	All	+0.787	.005	6	view →
ESCA	All	All	+2.001	<.001	5	view →
LUSC	All	All	−0.391	.002	5	view →
THCA	Male	II,III,IV	+0.616	.001	4	view →
LUAD	All	All	−0.251	.027	4	view →
CHOL	Female	All	+2.276	.002	2	view →
KIRP	All	IV	+1.502	.035	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

UBE2L6–HNSC

Open the HNSC breakdown →